

# Annie Wong-Beringer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8761454/publications.pdf>

Version: 2024-02-01

68  
papers

3,797  
citations

172207

29  
h-index

128067

60  
g-index

69  
all docs

69  
docs citations

69  
times ranked

3999  
citing authors

#	ARTICLE	IF	CITATIONS
1	In-Human Multiyear Evolution of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Causing Chronic Colonization and Intermittent Urinary Tract Infections: A Case Study. <i>MSphere</i> , 2022, 7, e0019022.	1.3	2
2	Impact of Socioeconomic Status and Race on Sepsis Epidemiology and Outcomes. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 194-209.	0.6	16
3	Risk factors and outcome associated with infection or colonization due to carbapenem-heteroresistant <i>Escherichia coli</i> . <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab036.	0.9	1
4	Cytokine measurements add value to clinical variables in predicting outcomes for <i>Staphylococcus aureus</i> bacteremia. <i>BMC Infectious Diseases</i> , 2021, 21, 317.	1.3	7
5	Improving the completeness of public metadata accompanying omics studies. <i>Genome Biology</i> , 2021, 22, 106.	3.8	22
6	Factors associated with prompt recovery among hospitalised patients with coronavirus disease 2019. <i>International Journal of Clinical Practice</i> , 2021, 75, e14818.	0.8	5
7	Increased Risk of Thrombocytopenia and Death in Patients with Bacteremia Caused by High Alpha Toxin-Producing Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Toxins</i> , 2021, 13, 726.	1.5	5
8	Defining the Breakpoint Duration of <i>Staphylococcus aureus</i> Bacteremia Predictive of Poor Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 70, 566-573.	2.9	82
9	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020, 71, 1361-1364.	2.9	142
10	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 281-284.	0.6	33
11	Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2020, 73, e1777-e1778.	2.9	1
12	Antibiotics Differentially Modulate Lipoteichoic Acid-Mediated Host Immune Response. <i>Antibiotics</i> , 2020, 9, 573.	1.5	5
13	Differential effects of antibiotics on neutrophils exposed to lipoteichoic acid derived from <i>Staphylococcus aureus</i> . <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 50.	1.7	6
14	Prevalence of the carbapenem-heteroresistant phenotype among ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1506-1512.	1.3	9
15	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 835-864.	0.5	640
16	Variable Release of Lipoteichoic Acid From <i>Staphylococcus aureus</i> Bloodstream Isolates Relates to Distinct Clinical Phenotypes, Strain Background, and Antibiotic Exposure. <i>Frontiers in Microbiology</i> , 2020, 11, 609280.	1.5	1
17	Utility of qSOFA score in identifying patients at risk for poor outcome in <i>Staphylococcus aureus</i> bacteremia. <i>BMC Infectious Diseases</i> , 2019, 19, 149.	1.3	12
18	Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy101.	0.4	21

#	ARTICLE	IF	CITATIONS
19	Risk factors for early return visits to the emergency department in patients with urinary tract infection. <i>American Journal of Emergency Medicine</i> , 2018, 36, 12-17.	0.7	35
20	Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for $\hat{I}^2$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	23
21	Emergency Department Urinary Antibiograms Differ by Specific Patient Group. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2629-2636.	1.8	27
22	Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	66
23	Clinically significant bacteria/pyuria-the author responds. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1561.	0.7	0
24	<i>Staphylococcus aureus</i> Bacteremia in Patients not Meeting Sepsis Criteria: Clinical Features, Host Immune Response and Outcomes. , 2017, 2, .		3
25	Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of <i>Pseudomonas aeruginosa</i> Differs by Type III Secretion Genotype. <i>Frontiers in Microbiology</i> , 2016, 7, 1591.	1.5	45
26	Wavelength-normalized spectroscopic analysis of <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> growth rates. <i>Biomedical Optics Express</i> , 2016, 7, 4034.	1.5	48
27	Differences in Clinical Presentation and Outcome Between Extended-Spectrum Beta-Lactamase (ESBL) Versus Non-ESBL Urinary Tract Infections (UTIs) in a Medically Underserved Population. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
28	Implementation of rapid diagnostics with antimicrobial stewardship. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1065-1075.	2.0	28
29	A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in <i>Staphylococcus aureus</i> Bacteremia*. <i>Critical Care Medicine</i> , 2016, 44, 671-679.	0.4	55
30	Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC $\geq 1$ mg/L: A Multicenter Evaluation. <i>Clinical Therapeutics</i> , 2016, 38, 16-30.	1.1	60
31	Rhesus $\hat{I}$ -defensin-1 (RTD-1) exhibits <i>in vitro</i> and <i>in vivo</i> activity against cystic fibrosis strains of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 181-188.	1.3	21
32	<i>In Vitro</i> Activity of Daptomycin in Combination with $\hat{I}^2$ -Lactams, Gentamicin, Rifampin, and Tigecycline against Daptomycin-Nonsusceptible Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4279-4288.	1.4	39
33	Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic <i>Klebsiella pneumoniae</i> infections. <i>American Journal of Infection Control</i> , 2015, 43, 1076-1080.	1.1	18
34	Microbicidal effects of $\hat{I}^{\pm}$ - and $\hat{I}$ -defensins against antibiotic-resistant <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> . <i>Innate Immunity</i> , 2015, 21, 17-29.	1.1	25
35	Risk of Developing Pneumonia Is Enhanced by the Combined Traits of Fluoroquinolone Resistance and Type III Secretion Virulence in Respiratory Isolates of <i>Pseudomonas aeruginosa</i> *. <i>Critical Care Medicine</i> , 2014, 42, 48-56.	0.4	29
36	The use of oligonucleotide recombination to generate isogenic mutants of clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Microbiological Methods</i> , 2014, 98, 23-25.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment. <i>BMC Infectious Diseases</i> , 2014, 14, 252.	1.3	20
38	Early Response Assessment to Guide Management of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections With Vancomycin Therapy. <i>Clinical Therapeutics</i> , 2013, 35, 995-1004.	1.1	10
39	Nebulizer Choice Affects the Airway Targeting of Amphotericin B Lipid Complex Aerosols. <i>Journal of Pharmacy Technology</i> , 2013, 29, 199-204.	0.5	1
40	Tigecycline Induction of Phenol-Soluble Modulins by Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4562-4565.	1.4	10
41	Differentiation in Quinolone Resistance by Virulence Genotype in <i>Pseudomonas aeruginosa</i> . <i>PLoS ONE</i> , 2012, 7, e42973.	1.1	60
42	Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 95-101.	1.1	162
43	Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant <i>Staphylococcus aureus</i> infections?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 124-130.	0.8	5
44	Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3278-3283.	1.4	83
45	Antivirulence Potential of TR-700 and Clindamycin on Clinical Isolates of <i>Staphylococcus aureus</i> Producing Phenol-Soluble Modulins. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4432-4435.	1.4	13
46	A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1765-1770.	1.3	49
47	Regulatory Oversight and Safety of Probiotic Use. <i>Emerging Infectious Diseases</i> , 2010, 16, 1661-1665.	2.0	154
48	An Antimicrobial Stewardship Program with a Focus on Reducing Fluoroquinolone Overuse. <i>Pharmacotherapy</i> , 2009, 29, 736-743.	1.2	46
49	Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Clinical Microbiology and Infection</i> , 2008, 14, 330-336.	2.8	67
50	Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, 378-385.	1.1	158
51	Reducing empirical use of fluoroquinolones for <i>Pseudomonas aeruginosa</i> infections improves outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 714-720.	1.3	14
52	High-Dose Vancomycin Therapy for Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. <i>Archives of Internal Medicine</i> , 2006, 166, 2138.	4.3	777
53	Suitability of Caspofungin for Aerosol Delivery. <i>Chest</i> , 2005, 128, 3711-3716.	0.4	27
54	Fluoroquinolone-resistant <i>Pseudomonas aeruginosa</i> : risk factors for acquisition and impact on outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 535-541.	1.3	72

#	ARTICLE	IF	CITATIONS
55	Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 565-570.	1.4	129
56	Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3676-3681.	1.4	44
57	Treating Serious Infections: Focus on Cefepime. <i>Pharmacotherapy</i> , 2004, 24, 216S-223S.	1.2	4
58	Persistent <i>Bacillus cereus</i> Bacteremia in an Immunocompetent Host. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, 294-296.	0.1	0
59	Systemic Antifungal Therapy: New Options, New Challenges. <i>Pharmacotherapy</i> , 2003, 23, 1441-1462.	1.2	50
60	Pneumococcal Vaccination in Hospitalized Elderly Patients: Role of the Pharmacist. <i>Pharmacotherapy</i> , 2003, 23, 199-208.	1.2	10
61	Applying patient selection criteria for drotrecogin alfa therapy in practice. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1345-1345.	0.5	11
62	Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused by <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> with Reduced Susceptibility to Ceftazidime. <i>Clinical Infectious Diseases</i> , 2002, 34, 135-146.	2.9	131
63	Implementing a program for switching from i.v. to oral antimicrobial therapy. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 1146-1149.	0.5	29
64	Economic Aspects of Antibacterial Adverse Effects. <i>Pharmacoeconomics</i> , 1998, 13, 35-49.	1.7	49
65	Predictive Performance of a Vancomycin Aminoglycoside Population Model. <i>Annals of Pharmacotherapy</i> , 1998, 32, 176-181.	0.9	3
66	Criteria for use of amphotericin B lipid complex injections in adults and children. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 2751-2752.	0.5	1
67	Safety and efficacy of Intralipid emulsions of amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 333-347.	1.3	39
68	Influence of timing of antibiotic administration on tissue concentrations during surgery. <i>American Journal of Surgery</i> , 1995, 169, 379-381.	0.9	33